Jollibee Plans U.S. Listing for International Business, Shares Rally 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
SMIC Shares Climb as China Boosts Chipmaking Support Amid AI Optimism 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Mercedes-Benz to Launch Advanced Urban Self-Driving System in the U.S., Challenging Tesla FSD 
Intel Unveils Panther Lake AI Laptop Chips at CES 2025, Marking Major 18A Manufacturing Milestone 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
Cathay Pacific Shares in Focus as Air China Plans Major Stake Reduction 
NEW YORK, March 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp. (“CTI BioPharma”) (NASDAQ:CTIC) pursuant or traceable to the Registration Statement and Prospectus issued in connection with the September 24, 2015 Public Offering and/or between March 4, 2014 and February 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/cti-biopharma.
The complaint alleges that the documents filed in connection with the offering contained materially false and misleading statements and/or omissions, including: (1) the detrimental effect on survival of experimental treatment pacritinib; (2) that the Company’s clinical trials demonstrated deaths associated with pacritinib usage; (3) that the Company’s new drug application for pacritinib would likely be withdrawn; (4) that, as such, the Company’s future revenues were impaired; and (5) that the company lacked adequate internal controls.
On February 8, 2016, it was revealed that the FDA had placed a partial hold on clinical studies of pacritinib, citing “identified…fatal and life-threatening safety issues in pacritinib-treated patients…”
If you suffered a loss in CTI BioPharma you have until April 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cti-biopharma.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
